Ezetimibe and Athletes: Why It Comes Up and What It Can and Cannot Do

Ezetimibe is an unglamorous prescription medicine for high cholesterol, yet its name increasingly appears in bodybuilding forums alongside the phrase "organ protection". The reasoning is that it might counteract the damaging lipid changes caused by anabolic steroids. Our editorial team looks at what ezetimibe actually is, what the evidence shows, and why it is no safety net for performance-enhancing drug use.

What ezetimibe is and how it works

Ezetimibe is a cholesterol absorption inhibitor. It blocks a transporter protein called Niemann-Pick C1-Like 1 (NPC1L1) in the lining of the small intestine, a target identified by Garcia-Calvo and colleagues in 2005. This reduces the amount of cholesterol absorbed from food and from bile.

With less cholesterol arriving from the gut, the liver increases the number of LDL receptors on its surface and removes more LDL particles from the blood. The net result is a fall in LDL cholesterol, typically of a moderate magnitude when ezetimibe is used on its own, and a larger fall when combined with a statin.

The licensed dose in the UK summary of product characteristics is 10 mg once daily, taken with or without food. Ezetimibe is a prescription-only medicine, available under the brand name Ezetrol and as generics, and also in fixed combinations with statins.

Unlike statins, ezetimibe does not act on cholesterol production in the liver, and it has relatively little effect on HDL cholesterol or triglycerides. This point is important when considering the lipid changes caused by anabolic steroids, which we discuss below.

Its place in UK cholesterol treatment

NICE technology appraisal TA385 recommends ezetimibe as an option for people with primary hypercholesterolaemia when statins are not tolerated or not appropriate, or in combination with a statin when LDL targets are not met. European guidelines from the ESC and EAS (2019) similarly position it as the usual second step after maximally tolerated statin therapy.

The key outcome trial is IMPROVE-IT, published in 2015. More than 18,000 patients who had recently experienced an acute coronary syndrome received either simvastatin plus ezetimibe or simvastatin alone. The combination produced lower LDL levels and a modest reduction in cardiovascular events over several years.

This evidence supports a simple principle confirmed by large genetic and clinical studies summarised by Ference and colleagues: LDL cholesterol causes atherosclerosis, and lowering it reduces risk roughly in proportion to how much and for how long it is lowered.

All of these data come from patients under medical care, with diagnosed lipid disorders or established heart disease, monitored with blood tests. They do not describe what happens when the drug is self-administered by healthy young people.

Why athletes and bodybuilders talk about it

Anabolic-androgenic steroids, particularly oral compounds, have well-documented effects on blood lipids. The Endocrine Society scientific statement by Pope and colleagues describes marked falls in HDL cholesterol and rises in LDL cholesterol, alongside increases in blood pressure and changes to heart structure.

Baggish and colleagues, studying long-term steroid users, found reduced heart pumping function and a greater burden of coronary artery plaque compared with non-using weightlifters. These are serious, potentially irreversible changes, and they are driven by several mechanisms, not just LDL.

The appeal of ezetimibe in this context is that it is well tolerated and lowers LDL. However, it does very little for the sharp fall in HDL, nothing for blood pressure, nothing for thickening of the heart muscle and nothing for raised haematocrit. Presenting it as "organ protection" therefore gives a dangerously incomplete picture.

It should also be noted that taking any prescription-only medicine without a prescription bypasses the safety checks of diagnosis, contraindication screening and monitoring. Our editorial team does not provide guidance on using ezetimibe in this way.

Limitations and side effects

In clinical use, ezetimibe is generally well tolerated. The most commonly reported side effects include abdominal pain, diarrhoea, flatulence, tiredness and headache. When combined with a statin, there may be slightly more frequent rises in liver enzymes and occasional muscle aches.

We also highlight szteroid vásárlás.

Rare but important adverse effects include allergic reactions, hepatitis, pancreatitis and, in combination with statins, muscle breakdown. The medicine is not recommended for people with moderate or severe liver impairment, a relevant point given that oral steroids themselves can strain the liver.

Ezetimibe interacts with ciclosporin and fibrates and requires extra monitoring in people taking anticoagulants such as warfarin. It is not recommended during pregnancy or breastfeeding.

Ezetimibe is not on the WADA Prohibited List. However, being "allowed" in sport does not mean it is appropriate for someone without a medical indication.

A safer approach to cardiovascular health

For any athlete concerned about cholesterol, the starting point is assessment, not a drug. A GP can arrange a full lipid profile and calculate cardiovascular risk, and may refer people with very high LDL for assessment of familial hypercholesterolaemia, which is common and frequently undiagnosed.

• Get a baseline lipid profile, blood pressure and, where relevant, haematocrit and liver tests.
• Prioritise diet: fibre, oily fish, nuts and limited saturated fat.
• Maintain regular aerobic exercise, not just resistance training.
• Avoid smoking and limit alcohol.
• Be honest with your doctor about any performance-enhancing substances — this changes how results are interpreted.

The most effective step for anyone experiencing steroid-related lipid changes is stopping exposure under medical supervision. Specialist harm-reduction services in the UK offer confidential health checks for people who use image- and performance-enhancing drugs.

If lipid-lowering medication is needed, a doctor will choose the agent based on the full risk profile, monitor blood results and adjust treatment safely.

Conclusions of the editorial team

Ezetimibe is a proven, well-tolerated prescription medicine that lowers LDL cholesterol by reducing intestinal absorption, with outcome benefits shown in patients with heart disease.

It does not neutralise the cardiovascular harms of anabolic steroids, which act through multiple routes including HDL suppression, hypertension and structural heart changes.

Concern about cholesterol should lead to proper testing and medical advice rather than self-medication.

Related reading: our articles on lipid panels for strength athletes, blood pressure monitoring, and the cardiovascular effects of anabolic steroids.

References

1. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102(23):8132–8137.
2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
3. National Institute for Health and Care Excellence. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385). London: NICE; 2016.
4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
5. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459–2472.
6. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
7. Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.